The Calu-3 cell line was derived from the carcinomatous lung tissue of a 25 year old Caucasian male suffering from adenocarcinoma. Before the cell line was established the patient had received therapy with bleomycin , cytoxan, and adriamycin. The tumorigenic, epithelial cells of the Calu-3 cell line are now used to produce a transfection host model for various types of lung cancer as well as other biomedical research. The Calu-3 transfection reagents established by Altogen Biosystems allow an intracellular delivery of pDNA, mRNA and siRNA and the recombinant protein expression desired in certain research. Calu-3 Transfection Reagent (Lung Carcinoma Cells, HTB-55)